Chapter 4 - Discovery

24 Questions | Total Attempts: 259

SettingsSettingsSettings
Discovery Quizzes & Trivia

Chapter 4 - learning about Drug Discovery. Part 4 in your quest for knowledge.


Questions and Answers
  • 1. 
    If you are a BDM, please describe in a short paragraph how you would use the information you learned in this chapter in a sales meeting. What key concepts would you use to sell M Squared?If you are a CSM, please describe how you would use the information learned in this chapter to identify a good consultant and pitch the opportunity to them.If you are in Operations, you already do enough hard work. Please write "I am Operations. Hear me roar".
  • 2. 
    Discovery functions are aligned with ______________.Groups involved with discovery efforts are usually organized by ____________, and subdivided by __________.
    • A. 

      Therapeutic area, major process stages, scientific specialty

    • B. 

      Major process stages, scientific specialty, therapeutic area

    • C. 

      Scientific specialty, therapeutic area, major process stages

  • 3. 
    What is a "lead" compound?
    • A. 

      Another term for active pharmaceutical ingredient

    • B. 

      A compound that exhibits certain properties that suggest its value as a starting point for drug discovery

    • C. 

      A compound that is known to possess certain properties that suggest its value in clinical trials

    • D. 

      A compound made of lead, or, in latin, plumbum, atomic #82

  • 4. 
    What future advances may lead to increased effiency with regards to identifying promising lead compounds?
    • A. 

      A shift to fully automated R&D efforts

    • B. 

      A shift to gene and protien based targeting

    • C. 

      A shift to greater focus on isomers and alternative formulations of current blockbuster compounds

    • D. 

      Reverting back to manually determing the crystalline structures of lead compounds.

  • 5. 
    What does NME stand for? (exact spelling/wording for credit)
  • 6. 
    The journey of drug discovery begins with isolation of a ___________ and progresses to perfection of a ________.
    • A. 

      Disease, drug

    • B. 

      Target, lead compound

    • C. 

      Disease, lead compound

    • D. 

      Target, active ingredient

  • 7. 
    Why is the discovery phase so important in controlling costs?
    • A. 

      This is where pharma companies identify promising compounds to be developed.

    • B. 

      This is where pharma companies identify less than promising coumpounds and eliminate them from cost-intensive development

    • C. 

      This is where drugs are discovered and is the basis for creating cash flow for the company as a whole.

    • D. 

      It isn't a factor in controlling costs.

  • 8. 
    How have certain facets of compound indetification been expedited in the modern day?
    • A. 

      The research teams have been diversified to bring input in from more types of scientists.

    • B. 

      The R&D teams have become more effective at manually identifying promising early stage compounds

    • C. 

      Researchers now use computer-based simulation and analysis to identify promising early stage compounds

    • D. 

      People are smarter now than they used to be.

  • 9. 
    What is the mission of drug discovery?
    • A. 

      To understand how a drug reacts on the body

    • B. 

      To determine the level at which the drug is toxic to create a safety threshold for patients using the drug.

    • C. 

      To improve the functioning of systems in the body by creating drugs that specifically target foreign antibodies.

    • D. 

      To understand the processes associated with a disease and to identigy a drug that can intervene in those processes

  • 10. 
    Discovery begins with the selction of a disease and a target. The target may be _________  in the market or completely ___________.
    • A. 

      In a new therapeutic area, or, a different class of drug entirely

    • B. 

      An isomer, or, a generic equivalent

    • C. 

      Previously established, or, new/innovative

    • D. 

      A bullleye or an X

  • 11. 
    What does NCE stand for? (exact spelling/wording for credit)
  • 12. 
    In vitro testing is _____________, while in vivo testing is _____________
    • A. 

      Harmful to the testing subject, not harmful to the testing subject

    • B. 

      Not harmful to the testing subject, harmful to the testing subject

    • C. 

      The testing in live animals, the testing of live tissue (from human or animal organs) in the lab

    • D. 

      The testing of live tissue (from human or animal organs) in the lab, the testing in live animals

  • 13. 
    When does true proof of concept (evidence that the drug is beneficial for the purpose being analyzed) occurs?
    • A. 

      Pre-clinical.

    • B. 

      Early Phase 1

    • C. 

      Early Phase 2

    • D. 

      In the discovery phase

  • 14. 
    Later-stage discovery involves:
    • A. 

      Discovering lead compounds at a later stage.

    • B. 

      Optimization of a set of molecules that appear to influence the target.

    • C. 

      Optimization of a target that shows promise.

    • D. 

      Discovering a secondary useage of a set of molecules/compounds during the optimization period.

  • 15. 
    Why do target profiles often get revised?
    • A. 

      In the event a secondary indication is discovered, it is necessary for the target profile to take into account the new usage.

    • B. 

      As time goes by, more data becomes available and it is necessary to revise the target profile to align with the new data.

    • C. 

      Because researchers realize that they were wrong in the first place.

    • D. 

      Side effects often occur in the discovery testing phase and it becomes evident that the drug is not an ideal candidate for a lead compound.

  • 16. 
    Why might a company elect not to continue to the development phase with a promising compound?
    • A. 

      Because it didnt reserve the patent in time so it would be a waste of money to develop the compound.

    • B. 

      Because the side effects outweight the benefits.

    • C. 

      Because it would be too expensive to develop the compound to a useable formulation.

    • D. 

      Because it does not align with the strategic goals of the company; and it becomes an outlicensing candidate.

  • 17. 
    Lead optimization is:
    • A. 

      The selection of the candidate with the most potential from the lead series/selecting a lead series out of a number of different compounds

    • B. 

      Optimizing the set of molecules/compound in order to indentify their potential.

    • C. 

      The minor modifications made to a team of sled dogs when a new team takes the lead at the Iditarod.

  • 18. 
    Why do Marketing and Discovery work so closely together?
    • A. 

      To develop marketing strategies based on the lead series the Discovery team has synthesized.

    • B. 

      To develop lead compounds that are based on the strategic goals of the company.

    • C. 

      To maintain a strong and clear messaging from discovery through to production.

    • D. 

      Come on, Beckett, they don't work closely together at all. Stop trying to trick me.

  • 19. 
    What is typically the primary research focus of R&D scientists?
    • A. 

      There is no focus, they're out to discover anything and everything.

    • B. 

      Focus is based on commercial imperative or a commitment to leveraging previously acquired intel.

    • C. 

      The focus is based on establishing generic bioequivalence.

    • D. 

      The primary focus is on the therapeutic area in which the pharma company competes.

  • 20. 
    At what point does the Discovery group apply for a patent?
    • A. 

      On day 1.

    • B. 

      When the lead compound(s) is/are identified.

    • C. 

      When the compound(s) begin/s to show promise

    • D. 

      When the full spectrum analysis con the compound/s has been conducted

  • 21. 
    What is pharmacogenomics?
    • A. 

      The study of gnomes involved with the illicit drug trade.

    • B. 

      The study of the pharmacology of genes.

    • C. 

      The study of the influence a cocktail of drugs on the entire genomic structure

    • D. 

      The study of genes and their relationship to drug action

  • 22. 
    Lead optimization includes all BUT:
    • A. 

      Testing of preliminary safety

    • B. 

      Pharmacology

    • C. 

      Pharmacokinetics

    • D. 

      Pharmacodynamics

    • E. 

      In vitro and in vivo testing

  • 23. 
    Once the target is identified, the ideal target product profile:
    • A. 

      Has both a high efficacy and level of side effects

    • B. 

      Optimally will combine high efficacy with a more favorable side effect profile

    • C. 

      Does not need to take into account the level of side effects if the condition is less serious

    • D. 

      Is a trade off between safety and efficacy.

  • 24. 
    True or False: Companies to not typically patent supporting research or manufacturing technologies.
    • A. 

      True

    • B. 

      False

Back to Top Back to top